Literature DB >> 11991556

Factors affecting compliance with allergen immunotherapy at a military medical center.

Daniel R More1, Larry L Hagan.   

Abstract

BACKGROUND: Allergen immunotherapy (AIT) is a safe and effective treatment for certain allergic disorders; however, noncompliance with therapy is common. We evaluated the compliance rates among groups receiving AIT at a military medical center and identified factors affecting compliance.
METHODS: The charts of the 381 actively enrolled patients in our AIT program were evaluated for patient compliance. Noncompliant patients were contacted to determine the reason for stopping therapy. Patients were then grouped by diagnosis, age, sex, military status, and schedule of AIT and evaluated for differences.
RESULTS: The overall compliance rate was 77.4%. The most common reasons for noncompliance included inconvenience, precluding medical condition, and adverse systemic reaction. There were no differences in compliance rates by diagnosis or sex. Noncompliant patients were younger than compliant patients, 35.4 years versus 42.4 years (P = 0.001); however, when patients were divided into three age categories (<18, 18 to 45, and >45 years), the youngest and oldest groups were more compliant (P < 0.001). Active-duty members were less compliant than retirees and family members, 65.7% versus 83.1% and 81.4%, respectively (P = 0.004). Patients receiving a conventional schedule of AIT were more compliant than those on a rush schedule, 80.0% versus 48.4% (P < 0.001).
CONCLUSIONS: Factors found to affect patient compliance with an AIT regimen at our military medical center include age, military status, and schedule of AIT. The most common reasons for noncompliance included inconvenience, precluding medical conditions, and adverse systemic reactions. Clinicians need to be aware of the factors limiting patient compliance with AIT in an attempt to maximize treatment effectiveness.

Entities:  

Mesh:

Year:  2002        PMID: 11991556     DOI: 10.1016/S1081-1206(10)62370-8

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  15 in total

Review 1.  How should allergists deal with local reactions to allergen immunotherapy?

Authors:  Michael S Tankersley
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

2.  [Persistence and frequency of prescriptions of subcutaneous allergen-specific immunotherapy (SCIT) prescribed within the German statutory health insurance].

Authors:  Christa Claes; Thomas Mittendorf; J-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-07-18

3.  Characterisation of patients with postmenopausal osteoporosis in French primary healthcare.

Authors:  Francis Blotman; Bernard Cortet; Pascal Hilliquin; Bernard Avouac; François-André Allaert; Denis Pouchain; Anne-Françoise Gaudin; François-Emery Cotté; Abdelkader El Hasnaoui
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  Subcutaneous Allergen Immunotherapy in Children: Real Life Compliance and Effect of COVID-19 Pandemic on Compliance.

Authors:  Elif Soyak Aytekin; Özge Soyer; Bülent E Şekerel; Ümit M Şahiner
Journal:  Int Arch Allergy Immunol       Date:  2021-04-22       Impact factor: 2.749

5.  Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic.

Authors:  Osman Ozan Yeğit; Semra Demir; Derya Ünal; Müge Olgaç; Kadriye Terzioğlu; Deniz Eyice Karabacak; Can Tüzer; Vehbi Ayhan; Bahattin Çolakoğlu; Suna Büyüköztürk; Aslı Gelincik
Journal:  Allergy       Date:  2021-05-10       Impact factor: 14.710

6.  Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis.

Authors:  Harold Kim; Susan Waserman; Jacques Hébert; Michael Blaiss; Harold Nelson; Peter Creticos; Amarjot Kaur; Jennifer Maloney; Ziliang Li; Hendrik Nolte
Journal:  Allergy Asthma Clin Immunol       Date:  2014-11-10       Impact factor: 3.406

7.  Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores.

Authors:  Michael Hessenberger; Richard Weiss; Esther E Weinberger; Christof Boehler; Josef Thalhamer; Sandra Scheiblhofer
Journal:  Vaccine       Date:  2012-12-27       Impact factor: 3.641

8.  Patient's compliance with allergen immunotherapy.

Authors:  Cristoforo Incorvaia; Marina Mauro; Erminia Ridolo; Paola Puccinelli; Massimiliano Liuzzo; Silvia Scurati; Franco Frati
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice.

Authors:  D Bach; R Weiss; M Hessenberger; S Kitzmueller; E E Weinberger; W D Krautgartner; C Hauser-Kronberger; C Boehler; J Thalhamer; S Scheiblhofer
Journal:  Allergy       Date:  2012-09-05       Impact factor: 13.146

10.  Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol.

Authors:  Melina Makatsori; Gianenrico Senna; Constantinos Pitsios; Ramon Lleonart; Ludger Klimek; Carlos Nunes; Maia Rukhadze; Barbara Rogala; Radoslaw Gawlik; Petr Panzner; Oliver Pfaar; Moises Calderon
Journal:  Clin Transl Allergy       Date:  2015-04-27       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.